<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39369049</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Effects of SZV-2649, a new multiple ion channel inhibitor mexiletine analogue.</ArticleTitle><Pagination><StartPage>23188</StartPage><MedlinePgn>23188</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23188</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-73576-5</ELocationID><Abstract><AbstractText>The antiarrhythmic and cardiac electrophysiological effects of SZV-2649 that contains a 2,6-diiodophenoxy moiety but lacks the benzofuran ring system present in amiodarone, were studied in mammalian cell line, rat and dog cardiac preparations. SZV-2649 exerted antiarrhythmic effects against coronary artery occlusion/reperfusion induced ventricular arrhythmias in rats and in acetylcholine- and burst stimulation induced atrial fibrillation in dogs. SZV-2649 inhibited hERG and GIRK currents in HEK cells (IC<sub>50</sub>: 342 and 529 nM, respectively). In canine ventricular myocytes, SZV-2649 (10 µM) decreased the densities of I<sub>Kr</sub>, and I<sub>to</sub> outward and I<sub>NaL</sub> and I<sub>CaL</sub> inward currents. The compound (2.5-10 µM) elicited Class IB type V<sub>max</sub> reducing and Class III type action potential duration prolonging effects in dog right ventricular muscle preparations. In canine atrial muscle, SZV-2629 (2.5-10 µM) moderately prolonged action potential duration and this effect was greatly augmented in preparations pretreated with 1 µM carbachol. In conclusion, SZV-2649, has antiarrhythmic effects based on its multiple ion channel blocking properties. Since its chemical structure substantially differs from that of amiodarone, it is expected that SZV-2649 would exhibit fewer adverse effects than the currently used most effective multichannel inhibitor drug amiodarone and may be a promising molecule for further development.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Aiman Saleh A</ForeName><Initials>ASA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naveed</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szabados</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szatmári</LastName><ForeName>István</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HUN-REN-SZTE Stereochemistry Research Group, Hungarian Research Network, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lőrinczi</LastName><ForeName>Bálint</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mátyus</LastName><ForeName>Péter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Organic Chemistry, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czompa</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Organic Chemistry, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orvos</LastName><ForeName>Péter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husti</LastName><ForeName>Zoltán</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornyik</LastName><ForeName>Tibor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topal</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Déri</LastName><ForeName>Szilvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HUN-REN-SZTE Research Group for Cardiovascular Pharmacology, Hungarian Research Network, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jost</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HUN-REN-SZTE Research Group for Cardiovascular Pharmacology, Hungarian Research Network, Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Research and Development and Innovation Centre of Excellence, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virág</LastName><ForeName>László</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Research and Development and Innovation Centre of Excellence, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bencsik</LastName><ForeName>Péter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baczkó</LastName><ForeName>István</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary. baczko.istvan@med.u-szeged.hu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Research and Development and Innovation Centre of Excellence, University of Szeged, Szeged, Hungary. baczko.istvan@med.u-szeged.hu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varró</LastName><ForeName>András</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary. varro.andras@med.u-szeged.hu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HUN-REN-SZTE Research Group for Cardiovascular Pharmacology, Hungarian Research Network, Szeged, Hungary. varro.andras@med.u-szeged.hu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Research and Development and Innovation Centre of Excellence, University of Szeged, Szeged, Hungary. varro.andras@med.u-szeged.hu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704</GrantID><Agency>Ministry of Human Capacities Hungary</Agency><Country /></Grant><Grant><GrantID>EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704</GrantID><Agency>Ministry of Human Capacities Hungary</Agency><Country /></Grant><Grant><GrantID>EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704</GrantID><Agency>Ministry of Human Capacities Hungary</Agency><Country /></Grant><Grant><GrantID>EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704</GrantID><Agency>Ministry of Human Capacities Hungary</Agency><Country /></Grant><Grant><GrantID>EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704</GrantID><Agency>Ministry of Human Capacities Hungary</Agency><Country /></Grant><Grant><GrantID>EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704</GrantID><Agency>Ministry of Human Capacities Hungary</Agency><Country /></Grant><Grant><GrantID>EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704</GrantID><Agency>Ministry of Human Capacities Hungary</Agency><Country /></Grant><Grant><GrantID>EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704</GrantID><Agency>Ministry of Human Capacities Hungary</Agency><Country /></Grant><Grant><GrantID>EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704</GrantID><Agency>Ministry of Human Capacities Hungary</Agency><Country /></Grant><Grant><GrantID>KDP-2020</GrantID><Agency>Ministry for Innovation and Technology, Cooperative Doctoral Programme</Agency><Country /></Grant><Grant><GrantID>RRF-2.3.1-21-2022-00001</GrantID><Agency>Recovery and Resilience Facility (RRF)</Agency><Country /></Grant><Grant><GrantID>NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040</GrantID><Agency>National Research Development and Innovation Office</Agency><Country /></Grant><Grant><GrantID>NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040</GrantID><Agency>National Research Development and Innovation Office</Agency><Country /></Grant><Grant><GrantID>NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040</GrantID><Agency>National Research Development and Innovation Office</Agency><Country /></Grant><Grant><GrantID>NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040</GrantID><Agency>National Research Development and Innovation Office</Agency><Country /></Grant><Grant><GrantID>NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040</GrantID><Agency>National Research Development and Innovation Office</Agency><Country /></Grant><Grant><GrantID>NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040</GrantID><Agency>National Research Development and Innovation Office</Agency><Country /></Grant><Grant><GrantID>NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040</GrantID><Agency>National Research Development and Innovation Office</Agency><Country /></Grant><Grant><GrantID>SZTE AOK-KKA 2021, SZGYA 2021, SZTE AOK-KKA 2022</GrantID><Agency>The Albert Szent-Györgyi Medical School institutional grant</Agency><Country /></Grant><Grant><GrantID>SZTE AOK-KKA 2021, SZGYA 2021, SZTE AOK-KKA 2022</GrantID><Agency>The Albert Szent-Györgyi Medical School institutional grant</Agency><Country /></Grant><Grant><GrantID>SZTE AOK-KKA 2021, SZGYA 2021, SZTE AOK-KKA 2022</GrantID><Agency>The Albert Szent-Györgyi Medical School institutional grant</Agency><Country /></Grant><Grant><GrantID>HUN-REN TKI project</GrantID><Agency>Hungarian Research Network</Agency><Country /></Grant><Grant><GrantID>HUN-REN TKI project</GrantID><Agency>Hungarian Research Network</Agency><Country /></Grant><Grant><GrantID>HUN-REN TKI project</GrantID><Agency>Hungarian Research Network</Agency><Country /></Grant><Grant><GrantID>bo_481_21</GrantID><Agency>Hungarian Academy of Sciences, János Bolyai Research Scholarships</Agency><Country /></Grant><Grant><GrantID>RRF-2.3.1-21-2022-00003</GrantID><Agency>National Heart Laboratory, Hungary</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>1U511HHV4Z</RegistryNumber><NameOfSubstance UI="D008801">Mexiletine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="Y">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008801" MajorTopicYN="Y">Mexiletine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="Y">Action Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39369049</ArticleId><ArticleId IdType="pmc">PMC11455950</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-73576-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-73576-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsao, C. W. et al. Heart Disease and Stroke Statistics—2022 update: a Report from the American Heart Association. Circulation. 145(8), e153–e639 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35078371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavousi, M. Differences in epidemiology and risk factors for Atrial Fibrillation between women and men. Front. Cardiovasc. Med.7, 3. 10.3389/fcvm.2020.00003 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025483</ArticleId><ArticleId IdType="pubmed">32118043</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldenberg, I. et al. Prior history of atrial fibrillation and arrhythmic outcomes: data from the WEARIT-II prospective registry. J. Cardiovasc. Electrophysiol.2110.1111/jce.16215 (2024 Feb). Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">38383981</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng, M., Lin, A. &amp; Nguyen, T. P. Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms. Front. Pharmacol. 11, 581837 doi: (2020). 10.3389/fphar.2020.581837. eCollection 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680856</ArticleId><ArticleId IdType="pubmed">33240090</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl. J. Med.321(6), 406–412. 10.1056/NEJM198908103210629 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2473403</ArticleId></ArticleIdList></Reference><Reference><Citation>Siebels, J., Cappato, R., Rüppel, R., Schneider, M. A. &amp; Kuck, K. H. Preliminary results of the Cardiac arrest study Hamburg (CASH). CASH investigators. Am. J. Cardiol.72(16), 109F–113F. 10.1016/0002-9149(93)90973-g (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8237823</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldo, A. L. et al. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am. J. Cardiol.75(15), 1023–1027. 10.1016/s0002-9149(99)80717-6 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7747682</ArticleId></ArticleIdList></Reference><Reference><Citation>Haugaard, M. M. et al. Pharmacologic inhibition of small-conductance calcium-activated potassium (SK) channels by NS8593 reveals atrial antiarrhythmic potential in horses. Heart Rhythm12(4), 825–835. 10.1016/j.hrthm.2014.12.028 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25542425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford, J. et al. The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation. Heart Rhythm13(2), 555–564. 10.1016/j.hrthm.2015.10.003 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768384</ArticleId><ArticleId IdType="pubmed">26455450</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravens, U. &amp; Wettwer, E. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovasc. Res.89(4), 776–785. 10.1093/cvr/cvq398 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21159668</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, T. et al. Small-conductance calcium-activated potassium channels in the heart: expression, regulation and pathological implications. Philos. Trans. R Soc. Lond. B Biol. Sci.378(1879), 20220171. 10.1098/rstb.2022.0171 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10150224</ArticleId><ArticleId IdType="pubmed">37122223</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, J., Wible, B., Li, G. R., Wang, Z. &amp; Nattel, S. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K + current in cultured adult human atrial myocytes. Circ. Res.80(4), 572–579. 10.1161/01.res.80.4.572 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9118489</ArticleId></ArticleIdList></Reference><Reference><Citation>Camm, A. J. et al. A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. Eur. Heart J. Cardiovasc. Pharmacother5(1), 21–28. 10.1093/ehjcvp/pvy022 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30052825</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudenchuk, P. J. et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl. J. Med.341(12), 871–878. 10.1056/NEJM199909163411203 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10486418</ArticleId></ArticleIdList></Reference><Reference><Citation>Mujović, N., Dobrev, D., Marinković, M., Russo, V. &amp; Potpara, T. S. The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacol. Res.151, 104521. 10.1016/j.phrs.2019.104521 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31756386</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinagawa, K., Shiroshita-Takeshita, A., Schram, G. &amp; Nattel, S. Effects of antiarrhythmic drugs on fibrillation in the remodelled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation. 107(10), 1440–1446. 10.1161/01.cir.0000055316.35552.74 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12642367</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravens, U. Antiarrhythmic therapy in atrial fibrillation. Pharmacol. Ther.128(1), 129–145. 10.1016/j.pharmthera.2010.06.004 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20624425</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisdale, J. E., Follin, S. L., Ordelova, A. &amp; Webb, C. R. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. J. Clin. Pharmacol.35(4), 351–356. 10.1002/j.1552-4604.1995.tb04072.x (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7650222</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan, R. J., Storey, G. C., Holt, D. W. &amp; Farmer, P. B. Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients. J. Pharm. Pharmacol.34(10), 638–643. 10.1111/j.2042-7158.1982.tb04692.x (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">6128385</ArticleId></ArticleIdList></Reference><Reference><Citation>Nattel, S. Pharmacodynamic studies of Amiodarone and its active N-Desetyl metabolite. J. Cardiovasc. Pharmacol.8 (4), 771–777 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">2427817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohajda, Z. et al. In vivo and cellular antiarrhythmic and cardiac electrophysiological effects of desethylamiodarone in dog cardiac preparations. Br. J. Pharmacol.179(13), 3382–3402. 10.1111/bph.15812 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35106755</ArticleId></ArticleIdList></Reference><Reference><Citation>Varró, A. &amp; Rabloczky, G. Antiarrhythmic effect of acute and chronic amiodarone treatment in conscious rats. J. Pharm. Pharmacol.38(10), 772–773. 10.1111/j.2042-7158.1986.tb04490.x (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">2879002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodama, I., Kamiya, K., Toyama, J. &amp; 20R-28R. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol.84(9A). 10.1016/s0002-9149(99)00698-0 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10568656</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillemare, E., Marion, A., Nisato, D. &amp; Gautier, P. Inhibitory effects of dronedarone on muscarinic K + current in guinea pig atrial cells. J. Cardiovasc. Pharmacol.36(6), 802–805. 10.1097/00005344-200012000-00017 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11117382</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, R. O. et al. Long-term amiodarone treatment causes cardioselective hypothyroid-like alteration in gene expression profile. Eur. J. Pharmacol.578, 270–278. 10.1016/j.ejphar.2007.09.039 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17991464</ArticleId></ArticleIdList></Reference><Reference><Citation>van Beeren, H. C., Bakker, O. &amp; Wiersinga, W. M. Desthylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the thyroid hormone alpha 1-receptor protein. Mol. Cell. Endocrinol.112, 15–19. 10.1016/0303-7207(95)03578-u (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7589780</ArticleId></ArticleIdList></Reference><Reference><Citation>van Beeren, H. C., Bakker, O. &amp; Wiereinga, W. M. Desethylamiodarone interferes with the binding of co-activator GRIP-1 to the beta 1-thyroid hormone receptor. FEBS Lett.481(3), 213–216. 10.1016/s0014-5793(00)01970-0 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11007966</ArticleId></ArticleIdList></Reference><Reference><Citation>Latham, K. R., Sellitti, D. F. &amp; Goldstein, R. E. Interaction of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors. J. Am. Coll. Cardiol.9(4), 872–876. 10.1016/s0735-1097(87)80244-9 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3558985</ArticleId></ArticleIdList></Reference><Reference><Citation>Taranto, V., Shvartsbeyn, M., Meehan, S. A. &amp; Siegel, L. J. Dronedarone-induced phototoxic dermatitis. Int. J. Dermatol.62 (12), 1553–1554. 10.1111/ijd.16845 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37700581</ArticleId></ArticleIdList></Reference><Reference><Citation>Tave, A. et al. Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics. Pharmacoepidemiol Drug Saf.30(10), 1353–1359. 10.1002/pds.5233 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8453764</ArticleId><ArticleId IdType="pubmed">33730412</ArticleId></ArticleIdList></Reference><Reference><Citation>Boriani, G. et al. Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. Europace. 21(12), 1764–1775. 10.1093/europace/euz193 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31324921</ArticleId></ArticleIdList></Reference><Reference><Citation>Matyus, P. et al. Development of pharmacophores for inhibitors of the rapid component of the cardiac delayed rectifier potassium current. Int. J. Quantum Chem.69, 21–30 (1998).</Citation></Reference><Reference><Citation>Kovesdi, I. et al. Application of neural networks in structure- activity relationships. Med. Res. Rev.3, 249–269 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10232652</ArticleId></ArticleIdList></Reference><Reference><Citation>Borosy, A., Keseru, K., Matyus, P. &amp; Penzes I. 3D QSAR study of class I antiarrhythmics. J. Mol. Struct. (Theochem). 503, 113–129 (2000).</Citation></Reference><Reference><Citation>Matyus, P., Rettegi, T., Varro, A. &amp; Papp, J. G. New antiarrhythmic agents: a conceptually novel approach. Med. Res. Rev.20(4), 294–303 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10861728</ArticleId></ArticleIdList></Reference><Reference><Citation>Aminoalkylated benzoxy compounds. For use in the Treatment of Cardiac Disorders. P2300429/10.</Citation></Reference><Reference><Citation>Varro, A., Nakaya, Y., Elharrar, V. &amp; Surawicz, B. Use-dependent effects of amiodarone on Vmax in cardiac Purkinje and ventricular muscle fibers. Eur. J. Pharmacol.112(3), 419–422. 10.1016/0014-2999(85)90791-5 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">4018143</ArticleId></ArticleIdList></Reference><Reference><Citation>Varró, A. et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br. J. Pharmacol.133(5), 625–634. 10.1038/sj.bjp.0704106 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1572824</ArticleId><ArticleId IdType="pubmed">11429385</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigger, J. T. Jr. &amp; Sahar, D. I. Clinical types of proarrhythmic response to antiarrhythmic drugs. Am. J. Cardiol.59(11). 10.1016/0002-9149(87)90195-0 (1987). 2E-9E.</Citation><ArticleIdList><ArticleId IdType="pubmed">3554950</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, F., Zhou, B., Sun, H. &amp; Wu, X. Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system. Front. Pharmacol.14, 1170039. 10.3389/fphar.2023.1170039 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10213327</ArticleId><ArticleId IdType="pubmed">37251345</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden, D.M. Mechanisms and management of proarrhythmia. Am. J. Cardiol.82(4A), 49I–57I. 10.1016/s0002-9149(98)00472-x (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9737654</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine, J. H., Morganroth, J. &amp; Kadish, A. H. Mechanisms and risk factors for proarrhythmia with type Ia compared with ic antiarrhythmic drug therapy. Circulation. 80(4), 1063–1069. 10.1161/01.cir.80.4.1063 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2676234</ArticleId></ArticleIdList></Reference><Reference><Citation>Herre, J. M. et al. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. Ann. Intern. Med.113(9), 671–676. 10.7326/0003-4819-113-9-671 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2121082</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian, D. G. et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European myocardial infarct amiodarone trial investigators. Lancet349(9053), 667–674. 10.1016/s0140-6736(96)09145-3 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9078197</ArticleId></ArticleIdList></Reference><Reference><Citation>Varró, A., Virág, L. &amp; Papp, J. G. Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Br. J. Pharmacol.1176), 1181–1186. 10.1111/j.1476-5381.1996.tb16713.x (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1909794</ArticleId><ArticleId IdType="pubmed">8882613</ArticleId></ArticleIdList></Reference><Reference><Citation>Abi-Gerges, N. et al. hERG subunit composition determines differential drug sensitivity. Br. J. Pharmacol.164(2b), 419–432. 10.1111/j.1476-5381.2011.01378.x (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188906</ArticleId><ArticleId IdType="pubmed">21449979</ArticleId></ArticleIdList></Reference><Reference><Citation>Orvos, P. et al. Evaluation of possible proarrhythmic potency: comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and native IKr currents and on Cardiac Action potential. Toxicol. Sci.168(2), 365–380. 10.1093/toxsci/kfy299 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30561737</ArticleId></ArticleIdList></Reference><Reference><Citation>Varro, A. et al. The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J. Physiol.523(Pt 1), 67–81. 10.1111/j.1469-7793.2000.00067.x (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2269783</ArticleId><ArticleId IdType="pubmed">10675203</ArticleId></ArticleIdList></Reference><Reference><Citation>Jost, M. et al. Ionic mechanisms limiting cardiac repolarization reserve in humans compared to dogs. J. Physiol.591(17), 4189–4206. 10.1113/jphysiol.2013.261198 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779111</ArticleId><ArticleId IdType="pubmed">23878377</ArticleId></ArticleIdList></Reference><Reference><Citation>Varró, A. et al. Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behavior. Physiol. Rev.101(3), 1083–1176. 10.1152/physrev.00024.2019 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33118864</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivek, S. N., Rakesh, K. &amp; Agarwal, D. D. Rapid and environment friendly method for acid free iodination of industrially important organics using I2/NaClO3/CH3OH system. Res. J. Chem. Environ.26(12), 31–43 (2022).</Citation></Reference><Reference><Citation>Dafei, M., Dongliang, L., Jin, W. &amp; Ting, Z. Guangfei, P. Process for Rapidly Synthesizing Ioxynil (CN 110105243 A, 2019).</Citation></Reference><Reference><Citation>Xiaohong, C. et al. D-A-D bent-core Bota liquid crystal compounds. CN 106675574 A, (2017).</Citation></Reference><Reference><Citation>Rocha, B. C. O., Perecim, G. P. &amp; Raminelli, C. Biomimetic iodofunctionalization of aromatic and heteroaromatic compounds catalyzed by Selenium Tetrachloride. SynOpen. 3, 142–147. 10.1055/s-0039-1690337 (2019).</Citation></Reference><Reference><Citation>Liu, D., Sanow, L. P. &amp; Zhang, C. Mitsunobu reactions of aliphatic alcohols and bulky phenols. Tetrahedron Lett.55(19), 3090–3092. 10.1016/j.tetlet.2014.03.138 (2014).</Citation></Reference><Reference><Citation>Lepore, S. D. &amp; He, Y. Use of Sonication for the Coupling of Sterically Hindered substrates in the phenolic Mitsunobu Reaction. J. Org. Chem.68(21), 8261–8263. 10.1021/jo0345751 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14535815</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurd, C. D., Perletz, P. &amp; Aryloxyacetones J. Am. Chem. Soc.68(1), 38–40 DOI:10.1021/ja01205a012 (1946).</Citation></Reference><Reference><Citation>Patrice, S., Steven, W. J., Guy, W. W. &amp; Daniel, C. E. Fungicides WO2005044008 A2, (2005).</Citation></Reference><Reference><Citation>Victor, B. R., Ronald, C. A., Jon, L. T., Tasneem, M. R. &amp; Stephen, T. Substituted indule derivatives for pharmaceutical composition for treating respiratory diseases. WO2005019171 A1, (2005).</Citation></Reference><Reference><Citation>Patrick, D. A. et al. Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives. Eur. J. Med. Chem.67, 310–324 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23871911</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel, S. et al. Identification of appropriate QTc formula in beagle dogs for nonclinical safety assessment. Regul. Toxicol. Pharmacol.89, 118–124. 10.1016/j.yrtph.2017.07.026 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28751260</ArticleId></ArticleIdList></Reference><Reference><Citation>Gömöri, K. et al. Cardioprotective effect of Novel Matrix Metalloproteinase inhibitors. Int. J. Mol. Sci.21(19), 6990. 10.3390/ijms21196990 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7582346</ArticleId><ArticleId IdType="pubmed">32977437</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis, M. J. et al. The Lambeth conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol. Ther.139(2), 213–248. 10.1016/j.pharmthera.2013.04.008 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23588158</ArticleId></ArticleIdList></Reference><Reference><Citation>Jost, N. et al. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation112(10), 1392–1399. 10.1161/CIRCULATIONAHA.105.550111 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16129791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristóf, A. et al. Diclofenac prolongs repolarization in ventricular muscle with impaired repolarization reserve. PLoS One. 7(12). 10.1371/journal.pone.0053255 (2012). e53255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534043</ArticleId><ArticleId IdType="pubmed">23300901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lengyel, C. et al. Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration. Br. J. Pharmacol.132(1), 101–110. 10.1038/sj.bjp.0703777 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1572535</ArticleId><ArticleId IdType="pubmed">11156566</ArticleId></ArticleIdList></Reference><Reference><Citation>Orvos, P. et al. Effects of Chelidonium majus extracts and major alkaloids on hERG potassium channels and on dog cardiac action potential - a safety approach. Fitoterapia100, 156–165. 10.1016/j.fitote.2014.11.023 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25481375</ArticleId></ArticleIdList></Reference><Reference><Citation>Kúsz, N. et al. Diterpenoids from Euphorbia dulcis with Potassium Ion Channel Inhibitory activity with Selective G Protein-Activated Inwardly Rectifying Ion Channel (GIRK) blocking effect. J. Nat. Prod.81(11), 2483–2492. 10.1021/acs.jnatprod.8b00500 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30411614</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>